Home › Companies › GNLX

Genelux

GNLX Lead: Phase 3 1 Biotech Distilled article ↓

Oncology Gene Therapy

Most recent annual filing: 2026-03-15

Pipeline (3 active programs)

Olvi-Vec

olvimulogene nanivacirepvec · GLV-1h68 · GL-ONC1

Gene Therapy

Platinum-Resistant/Refractory Ovarian Cancer Phase 3 intraperitoneal
Non-Small Cell Lung Cancer Phase 2 intravenous Newsoara
Small Cell Lung Cancer Phase 1 intravenous Newsoara

Technology platforms

CHOICE

Proprietary selection technology and discovery/development platform based on a collection of vaccinia virus (VACV) strains selected on multiple in vitro and in vivo criteria; generates oncolytic VACV immunotherapy candidates for multiple solid tumor types in monotherapy and combination settings

Biotech Distilled coverage (1)

2026-07-15 Genelux Corporation (GNLX) — Scientific Deep Dive for Olvi-Vec and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.